Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
OBJECTIVES: Use of immune checkpoint inhibitors as first-line treatment for advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) remains controversial. Clinical trials comparing single-drug immunotherapy (IO) with immunotherapy plus chemotherapy (IC) are lacking. We aimed to compare the effic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682470/ https://www.ncbi.nlm.nih.gov/pubmed/33444168 http://dx.doi.org/10.1136/bmjopen-2019-034010 |
_version_ | 1783612693253455872 |
---|---|
author | Li, Lingling Xu, Fei Chen, Yu Ren, Xiaoli Liu, Yu Chen, Yuan Xia, Shu |
author_facet | Li, Lingling Xu, Fei Chen, Yu Ren, Xiaoli Liu, Yu Chen, Yuan Xia, Shu |
author_sort | Li, Lingling |
collection | PubMed |
description | OBJECTIVES: Use of immune checkpoint inhibitors as first-line treatment for advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) remains controversial. Clinical trials comparing single-drug immunotherapy (IO) with immunotherapy plus chemotherapy (IC) are lacking. We aimed to compare the efficacy of IO alone with that of IC as first-line treatment for advanced NSCLC. DESIGN: Systematic review. DATA SOURCES: PubMed, the Cochrane Library and Embase for related studies on NSCLC; ClinicalTrials.gov, American Society of Clinical Oncology Meeting Library and World Conference on Lung Cancer for relevant conference abstracts (to July 2019). ELIGIBILITY CRITERIA: Articles meeting the following criteria were selected: (1) randomised controlled trials on NSCLC treatment, (2) all individuals in the studies had not received treatment previously and (3) research on IO monotherapy using programmed death-1/programmed death ligand-1 (PD-L1) inhibitors or IC. DATA EXTRACTION AND SYNTHESIS: After reading the original literature, two reviewers independently extracted the relevant information. The primary outcomes were progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). We also extracted data on treatment-related adverse events and immune-related adverse events (irAEs). RESULTS: Overall, 10 randomised controlled clinical trials (n=5765) were included. As first-line treatment for advanced NSCLC, IC tended to yield better PFS, OS and ORR than did IO. Furthermore, IC yielded significantly better PFS than IO when tumour PD-L1 expression was at least 50% (HR: 1.81, 95% CI: 1.18 to 2.78) and yielded a better OS and PFS when tumour PD-L1 expression was at least 1%; IO resulted in fewer adverse events than did IC. However, the incidence of irAEs was higher for IO than for IC. CONCLUSIONS: The findings of the indirect comparison indicate that IC as first-line treatment for advanced NSCLC is significantly more effective than IO in patients with PD-L1 expression in at least 50% of tumour cells. TRIAL REGISTRATION NUMBER: CRD 42018116589. |
format | Online Article Text |
id | pubmed-7682470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-76824702020-11-24 Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review Li, Lingling Xu, Fei Chen, Yu Ren, Xiaoli Liu, Yu Chen, Yuan Xia, Shu BMJ Open Oncology OBJECTIVES: Use of immune checkpoint inhibitors as first-line treatment for advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) remains controversial. Clinical trials comparing single-drug immunotherapy (IO) with immunotherapy plus chemotherapy (IC) are lacking. We aimed to compare the efficacy of IO alone with that of IC as first-line treatment for advanced NSCLC. DESIGN: Systematic review. DATA SOURCES: PubMed, the Cochrane Library and Embase for related studies on NSCLC; ClinicalTrials.gov, American Society of Clinical Oncology Meeting Library and World Conference on Lung Cancer for relevant conference abstracts (to July 2019). ELIGIBILITY CRITERIA: Articles meeting the following criteria were selected: (1) randomised controlled trials on NSCLC treatment, (2) all individuals in the studies had not received treatment previously and (3) research on IO monotherapy using programmed death-1/programmed death ligand-1 (PD-L1) inhibitors or IC. DATA EXTRACTION AND SYNTHESIS: After reading the original literature, two reviewers independently extracted the relevant information. The primary outcomes were progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). We also extracted data on treatment-related adverse events and immune-related adverse events (irAEs). RESULTS: Overall, 10 randomised controlled clinical trials (n=5765) were included. As first-line treatment for advanced NSCLC, IC tended to yield better PFS, OS and ORR than did IO. Furthermore, IC yielded significantly better PFS than IO when tumour PD-L1 expression was at least 50% (HR: 1.81, 95% CI: 1.18 to 2.78) and yielded a better OS and PFS when tumour PD-L1 expression was at least 1%; IO resulted in fewer adverse events than did IC. However, the incidence of irAEs was higher for IO than for IC. CONCLUSIONS: The findings of the indirect comparison indicate that IC as first-line treatment for advanced NSCLC is significantly more effective than IO in patients with PD-L1 expression in at least 50% of tumour cells. TRIAL REGISTRATION NUMBER: CRD 42018116589. BMJ Publishing Group 2020-11-20 /pmc/articles/PMC7682470/ /pubmed/33444168 http://dx.doi.org/10.1136/bmjopen-2019-034010 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Oncology Li, Lingling Xu, Fei Chen, Yu Ren, Xiaoli Liu, Yu Chen, Yuan Xia, Shu Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review |
title | Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review |
title_full | Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review |
title_fullStr | Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review |
title_full_unstemmed | Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review |
title_short | Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review |
title_sort | indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682470/ https://www.ncbi.nlm.nih.gov/pubmed/33444168 http://dx.doi.org/10.1136/bmjopen-2019-034010 |
work_keys_str_mv | AT lilingling indirectcomparisonbetweenimmunotherapyaloneandimmunotherapypluschemotherapyasfirstlinetreatmentforadvancednonsmallcelllungcancerasystematicreview AT xufei indirectcomparisonbetweenimmunotherapyaloneandimmunotherapypluschemotherapyasfirstlinetreatmentforadvancednonsmallcelllungcancerasystematicreview AT chenyu indirectcomparisonbetweenimmunotherapyaloneandimmunotherapypluschemotherapyasfirstlinetreatmentforadvancednonsmallcelllungcancerasystematicreview AT renxiaoli indirectcomparisonbetweenimmunotherapyaloneandimmunotherapypluschemotherapyasfirstlinetreatmentforadvancednonsmallcelllungcancerasystematicreview AT liuyu indirectcomparisonbetweenimmunotherapyaloneandimmunotherapypluschemotherapyasfirstlinetreatmentforadvancednonsmallcelllungcancerasystematicreview AT chenyuan indirectcomparisonbetweenimmunotherapyaloneandimmunotherapypluschemotherapyasfirstlinetreatmentforadvancednonsmallcelllungcancerasystematicreview AT xiashu indirectcomparisonbetweenimmunotherapyaloneandimmunotherapypluschemotherapyasfirstlinetreatmentforadvancednonsmallcelllungcancerasystematicreview |